Impacting News- Prohost Biotech - Exclusive Biotech Research

Category: Impacting News

Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra for the Patients with NASH That Have Moderate to Advanced Liver Fibrosis

Madrigal Pharmaceuticals in the NEWS Yesterday, March 14, 2024 Madrigal Pharmaceuticals ( MDGL ) announced that the U.S. FDA has granted accelerated approval for the firm’s product Rezdiffra (resmetirom) in conjunction with diet and exercise for the treatment of adults...

March 15, 2024

Anavex Life Sciences Product Blarcamesine for Alzheimer’s Disease Receives Promising News from the EMA

Anavex Life Sciences Promising News From Anavex Life Sciences ( AVXL ) we learned that The Committee for Medicinal Products for Human Use ( CHMP ) within the European Medicines agency ( EMA ) agreed that oral blarcamesine for Alzheimer’s disease is...

December 20, 2023

Arcus Biosciences Stock Price Skyrockets Following Gilead Sciences Decision to Augment Their Partnership

Gilead Sciences Collaboration with Arcus Biosciences Sends Stock Through the Roof There is no doubt that Gilead Sciences ( GILD ) is appreciating Arcus Biosciences ( RCUS ) and their collaboration. Both companies announced today that Gilead has exercised its...

November 18, 2021

Why Arcturus Therapeutics Holdings' Pipeline Products are Promising

The information is the first of a few biotech Companies that we believe are promising in treating severe devastating untreatable sicknesses. Arcturus Therapeutics Holdings Based in San Diego, California, Arcturus Therapeutics Holdings ( ARCT ) was founded in 2013. The Company...

December 27, 2023

Let's Talk About 3 Firms with Important News: Cassava Sciences, Vertex Pharmaceuticals and Gilead Sciences

Cassava Sciences, Vertex Pharmaceuticals and Gilead Sciences All Have Good News Cassava Sciences & Alzheimer's Disease Cassava Sciences ( SAVA ) announced the initiation of a second Phase 3 trial of simufilam, its investigational drug for Alzheimer’s disease. This second...

November 19, 2021

Sarepta Therapeutics Submits Efficacy Supplement to Expand the ELEVIDYS Label

Sarepta Therapeutics in the NEWS On 12, 22, 2023, Sarepta Therapeutics ( SRPT ) - a precision genetic medicine for rare diseases, announced submission of an efficacy supplement to the Biologics License Application ( BLA ) for ELEVIDYS (delandistrogene moxeparvovec-rokl)...

December 28, 2023

The FDA Granted Orphan Drug Designation to Regenxbio Investigational Gene Therapy Drug RGX-202 for Duchenne Muscular Dystrophy

Regenxbio Granted Orphan Drug Designation for RGX-202 Regenxbio ( RGNX ) announced the U.S. FDA granted Orphan Drug Designation for RGX-202 - a potential one-time gene therapy for the treatment of Duchenne muscular dystrophy. RGX-202 is designed to deliver a...

November 23, 2021

Cytokinetics Announces Positive Results from a Pivotal Phase 3 Clinical Trial of Aficamten

Cytokinetics We recently became enthusiastic about Cytokinetics’ ( CYTK ) current clinical trial results. A few days ago, Cytokinetics announced positive results from SEQUOIA-HCM (Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of Aficamten in HCM), the pivotal Phase 3...

December 29, 2023

AbbVie Inc's Two Different, Yet, Positive Impacting News

AbbiVie Inc's Acquisition and Approval 1. AbbVie's Acquisition AbbVie Inc. ( ABBV ) and Landos Biopharma, Inc . ( LABP ) announced a definitive agreement under which AbbVie will acquire Landos Biopharma, a clinical stage biopharmaceutical firm focused on...

March 26, 2024

Yes, Compugen's Stock is Soaring, But Why?

Compugen's Soaring Stock Many recent events led to Compugen's ( CGEN ) soaring stock after a huge decline in its price. In spite of the tremendous stock decline, Prohost never doubted the fact that Compugen has solid scientific fundamentals and...

January 2, 2024

Search ProhostBiotech

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis

September 19, 2024

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024